See more : Blue Water Petroleum Corp. (BWPC) Income Statement Analysis – Financial Results
Complete financial analysis of Nanobiotix S.A. (NBTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nanobiotix S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Pantheon Resources Plc (PTHRF) Income Statement Analysis – Financial Results
- PT Global Sukses Solusi Tbk (RUNS.JK) Income Statement Analysis – Financial Results
- Anhui Expressway Company Limited (600012.SS) Income Statement Analysis – Financial Results
- Otokar Otomotiv ve Savunma Sanayi A.S. (OTKAR.IS) Income Statement Analysis – Financial Results
- Dogwood Therapeutics, Inc. (DWTX) Income Statement Analysis – Financial Results
Nanobiotix S.A. (NBTX)
About Nanobiotix S.A.
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.06M | 4.78M | 10.00K | 50.00K | 68.00K | 116.00K | 251.97K | 1.56M | 265.54K | 967.50K | 184.94K | 74.15K | 1.36M |
| Cost of Revenue | 0.00 | 985.00K | 0.00 | 0.00 | 0.00 | 0.00 | 345.59K | 436.31K | 359.61K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 30.06M | 3.79M | 10.00K | 50.00K | 68.00K | 116.00K | -93.62K | 1.12M | -94.07K | 967.50K | 184.94K | 74.15K | 1.36M |
| Gross Profit Ratio | 100.00% | 79.38% | 100.00% | 100.00% | 100.00% | 100.00% | -37.16% | 72.00% | -35.42% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 38.40M | 32.64M | 30.38M | 24.33M | 30.41M | 20.89M | 16.34M | 16.92M | 13.90M | 8.08M | 6.03M | 4.31M | 5.21M |
| General & Administrative | 21.66M | 17.48M | 19.43M | 14.27M | 18.64M | 12.62M | 12.34M | 10.26M | 7.19M | 4.30M | 3.61M | 1.81M | 1.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 21.66M | 17.48M | 19.43M | 14.27M | 18.64M | 12.62M | 12.34M | 10.26M | 7.19M | 4.30M | 3.61M | 1.81M | 1.30M |
| Other Expenses | -3.22M | -3.41M | -2.64M | -2.07M | -2.20M | -3.33M | -337.89K | 160.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 56.84M | 46.70M | 47.18M | 36.53M | 46.85M | 30.18M | 25.52M | 23.41M | 17.41M | 10.59M | 8.36M | 5.23M | 5.23M |
| Cost & Expenses | 56.84M | 46.70M | 47.18M | 36.53M | 46.85M | 30.18M | 25.52M | 23.41M | 17.41M | 10.59M | 8.36M | 5.23M | 5.23M |
| Interest Income | 1.22M | 256.00K | 6.17M | 4.68M | 105.00K | 34.00K | 33.03K | 59.49K | 183.22K | 196.65K | 59.06K | 46.00 | 11.53K |
| Interest Expense | 7.98M | 5.84M | 590.00K | 333.00K | 4.79M | 847.00K | 108.37K | 102.20K | 59.52K | 55.73K | 24.57K | 77.01K | 30.77K |
| Depreciation & Amortization | 1.51M | 1.50M | 1.56M | 1.76M | 1.77M | 569.00K | 345.59K | 436.31K | 456.08K | 307.56K | 233.93K | 146.53K | 197.62K |
| EBITDA | -30.09M | -45.15M | -45.61M | -31.49M | -44.78M | -29.33M | -25.55M | -21.21M | -16.49M | -9.11M | -7.89M | -5.01M | -5.02M |
| EBITDA Ratio | -100.09% | -1,084.63% | -409,950.00% | -59,906.00% | -65,845.59% | -25,282.76% | -10,172.33% | -1,360.96% | -6,208.97% | -942.01% | -4,264.36% | -6,781.21% | -368.90% |
| Operating Income | -26.78M | -46.70M | -52.58M | -36.43M | -46.78M | -30.07M | -25.27M | -21.85M | -17.14M | -9.62M | -8.18M | -5.15M | -5.23M |
| Operating Income Ratio | -89.09% | -977.85% | -525,790.00% | -72,856.00% | -68,792.65% | -25,919.83% | -10,027.88% | -1,402.65% | -6,455.32% | -994.29% | -4,422.79% | -6,948.91% | -384.27% |
| Total Other Income/Expenses | -12.80M | -10.33M | 5.58M | 2.85M | -4.13M | -278.00K | -876.00K | 64.61K | 138.56K | 142.52K | 34.50K | -99.18K | -19.34K |
| Income Before Tax | -39.58M | -57.03M | -47.00M | -33.61M | -50.91M | -30.35M | -26.14M | -21.79M | -17.00M | -9.48M | -8.14M | -5.25M | -5.25M |
| Income Before Tax Ratio | -131.68% | -1,194.16% | -469,990.00% | -67,228.00% | -74,870.59% | -26,159.48% | -10,375.61% | -1,398.50% | -6,403.14% | -979.56% | -4,404.14% | -7,082.66% | -385.69% |
| Income Tax Expense | 120.00K | 10.00K | 5.00K | 9.00K | 3.00K | -449.00K | 20.00 | 90.43K | 37.58K | 79.27K | 22.91K | 78.89K | 30.67K |
| Net Income | -39.70M | -57.04M | -47.00M | -33.62M | -50.92M | -29.90M | -26.14M | -21.88M | -17.00M | -9.56M | -8.14M | -5.33M | -5.25M |
| Net Income Ratio | -132.08% | -1,194.37% | -470,040.00% | -67,246.00% | -74,875.00% | -25,772.41% | -10,375.62% | -1,404.31% | -6,403.14% | -987.75% | -4,404.14% | -7,189.05% | -385.69% |
| EPS | -1.08 | -1.64 | -1.35 | -1.38 | -2.35 | -1.52 | -1.50 | -1.43 | -1.20 | -0.74 | -0.76 | -0.65 | -3.42 |
| EPS Diluted | -1.08 | -1.64 | -1.35 | -1.38 | -2.35 | -1.52 | -1.50 | -1.43 | -1.20 | -0.74 | -0.76 | -0.65 | -3.42 |
| Weighted Avg Shares Out | 36.93M | 34.85M | 34.73M | 24.39M | 21.63M | 19.62M | 17.43M | 15.28M | 14.14M | 12.87M | 10.75M | 8.22M | 1.54M |
| Weighted Avg Shares Out (Dil) | 36.93M | 34.85M | 34.73M | 24.39M | 21.63M | 19.63M | 17.48M | 15.28M | 14.14M | 12.87M | 10.75M | 8.22M | 1.54M |
NANOBIOTIX Provides Business Update and Reports Financial Results for the First Half of 2021
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and announced its...
Nanobiotix Provides Second Quarter Operational and Financial Update
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Nanobiotix (Euronext: NANO – NASDAQ: NBTX) provides second quarter operational and financial update.
Nanobiotix Starts New NBTXR3 Study In Lung Cancer Patients
Nanobiotix (NASDAQ: NBTX) initiated a new Phase 1 study evaluating NBTXR3 activated by radiation therapy (RT) for patients with non-small cell lung cancer (NSCLC) amenable to re-irradiation. The study will investigate the safety and optimal dose of NBTXR3 for non-small cell lung cancer...
NANOBIOTIX to Host Virtual KOL Event Discussing Potential First-in-Class Radioenhancer NBTXR3 In Immunotherapy on June 11, 2021
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it...
Nanobiotix's Nanoparticle Technology Shows Tumor-Killing Effect in Early-Stage Head & Neck Cancer
Nanobiotix (NASDAQ: NBTX), ahead of the 2021 Annual Meeting of the American Society for Clinical Oncology meeting, has said that its nanoparticles were able to shrink tumors in about 77% of patients in a small Phase 1 trial. NBTXR3 consists of crystalline...
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #ASCO--Regulatory News: NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the upcoming presentation of...
Nanobiotix Announces the Appointment of Dr. Gary Phillips as Chairman of the Nanobiotix Supervisory Board
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Gary Phillips, MD,...
CORRECTING and REPLACING Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #ASCO--Regulatory News: Please replace the release dated May 19, 2021 with the following corrected version due to multiple revisions. NANOBIOTIX ANNOUNCES UPDATED RESULTS FROM PRIORITY PATHWAYS IN HEAD AND NECK CANCER AND IMMUNOTHERAPY FOR...
Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #ASCO--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the upcoming presentation of...
Nanobiotix, LianBio Ink NBTXR3 Development Pact In Asia For Solid Tumor Settings
Nanobiotix (NASDAQ: NBTX) has announced a partnership with LianBio to develop and commercialize Nanobiotix's lead product candidate NBTXR3, in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore, and Thailand. NBTXR3 comprises functionalized hafnium oxide nanoparticles that are administered via one-time intratumoral injection...
Source: https://incomestatements.info
Category: Stock Reports